Serina Therapeutics (SER) Current Deferred Revenue (2017 - 2020)

Serina Therapeutics has disclosed Current Deferred Revenue across 4 years of filings, most recently posting $300000.0 for Q4 2020.

• In Q4 2020, Current Deferred Revenue rose 6.01% year-over-year to $300000.0; the TTM figure through Dec 2020 stood at $300000.0 (up 6.01% YoY), while the FY2020 annual figure was $300000.0, up 6.01% from the prior year.
• Current Deferred Revenue came in at $300000.0 for Q4 2020 at Serina Therapeutics, up from $255000.0 in the prior quarter.
• In the past five years, Current Deferred Revenue ranged from a high of $407000.0 in Q1 2020 to a low of $180000.0 in Q4 2017.
• Average Current Deferred Revenue over 4 years is $283888.9, with a median of $283000.0 recorded in 2019.
• Year-over-year, Current Deferred Revenue surged 76.11% in 2018 and declined 10.73% in 2019.
• Over 4 years, Current Deferred Revenue stood at $180000.0 in 2017, then surged by 76.11% to $317000.0 in 2018, then decreased by 10.73% to $283000.0 in 2019, then climbed by 6.01% to $300000.0 in 2020.
• Per Business Quant data, the three most recent Current Deferred Revenue figures were $300000.0 in Q4 2020, $255000.0 in Q3 2020, and $328000.0 in Q2 2020.